Tempest Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Tempest Therapeutics, Inc. (TPST) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$6.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$5.90M.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$8.76M.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$6.90M.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$8.30M.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$22.56M.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$8.96M, a 210.98% decline from fiscal 2023.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $8.07M.
- Tempest Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$20.23M, a 161.29% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.93M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$5.90M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$22.56M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$22.75M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$15.99M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$8.76M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$8.96M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$16.76M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$8.11M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$6.90M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $8.07M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$20.09M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$13.63M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$8.30M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$20.23M 10-K · filed 2024-03-19 | |||
| 2022-06-30 | $160.00K 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | -$5.71M 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $33.01M 10-K · filed 2023-03-22 | |||
| 2021-06-30 | $49.64M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $8.62M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $15.58M 10-K · filed 2022-03-29 | |||
| 2020-06-30 | $24.44M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |